Topics:
Thoracic Malignancies • Medical Oncology
What is your preferred first line therapy for advanced NSCLC with an EGFR activating mutation?
Does the more recent NEJ026 trial describing benefit from Bevacizumab plus Erlotinib over Erlotinib alone in patients with EGFR driver mutations change current practice?
https://clinicaltrials.gov/ct2/show/NCT02633189
Answer from: Medical Oncologist at Academic Institution
My current off-protocol approach is osimertinib as a single agent, though combining osimertinib with bevacizumab is being tested in an interesting clinical trial. The bev-erlo combination trials are very small with small hints of a survival benefit, but definitely improved progression-free sur...
Sign in or Register to read more